Follicular stem cells

Biologic

IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Follicular stem cells is one of 23 biologic programs targeting Alopecia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AlopeciaActive, not recruiting

AlopeciaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Alopecia

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Otezla

Amgen

Approved

1 3

Zolymbus

Opzelura

Olumiant

Raptiva

1 7

Anzupgo

Alnylam Pharmaceuticals

Phase 2

1 8

Cosentyx

Avodart

2 10

Rogaine

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alopecia1 trial

Treatment of Alopecia Using Follicular Stem Cells

Unknown status·IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus·Phase 1/2·NCT05210452·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Follicular stem cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Follicular stem cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Follicular stem cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: IInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Follicular stem cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alopecia1 trial

References

Drug Info

Quick Facts

Related News